Definitive Contract 75N91022C00032
Award Date 9/16/22
Potential Completion Date 10/15/23
Potential Value $386K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Sharon, MA 02067, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
8
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- The National Cancer Institute awarded a $1,995,119 firm-fixed-price Phase II SBIR contract to Boston Cell Standards Inc., a for-profit manufacturer of medical devices, diagnostics, and related services. The contract, which is set aside for small businesses, is to develop quantitative traceable reference materials for use in cancer detection and diagnostics. This award builds on a previous $385,889 Phase I SBIR contract with the National Cancer Institute. Boston Cell Standards has also received...
- This is a $197,673 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Molecular Express, Inc., a minority-owned and self-certified small disadvantaged business. The contract is for the development of a commercial point-of-care device capable of electronically sensing tumor cells and molecular cancer biomarkers in a patient's circulating peripheral blood. This research project...
- <p>The National Cancer Institute (NCI) awarded a $249,792 Small Business Innovation Research (SBIR) Phase I contract to Biotex, Inc. to develop "Instruments and Devices that Preserve Molecular Profiles in Tumors" under SBIR Topic 257. The contract is a firm-fixed-price definitive contract with a period of performance ending on June 30, 2010. This SBIR contract supports the NCI's research objectives related to advancing cancer diagnostics and therapeutics.</p>
- This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
- This is a $273,600 firm-fixed-price definitive contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to JBS Science Inc., a small business biotechnology company. The contract is for the development of a cell-free circulating DNA-based assay for liver cancer screening. This award supports NCI's efforts to advance innovative molecular diagnostic technologies for cancer detection and monitoring. As a small business set-aside contract, the...
- <p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
- <p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>
- This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the "SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM" and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...
- This is a $198,641 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Nanocellect Biomedical Inc., a for-profit biotechnology company. The contract is for the development of a "CTC Label and Capture by Lab-on-a-Chip Flow-Cytometry" solution, which aligns with the NCI's research interests. Nanocellect Biomedical is an innovative provider of automated cell analysis, sorting, and dispensing equipment and services, with a strong...
- This is a $148,828 Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of Health and Human Services (HHS) to Meso Scale Diagnostics LLC, a small business provider of assay development services, laboratory testing equipment, and immunoassays. The contract, titled "TOPIC 238 AUTOMATED MULTI-ARRAY PLATFORM FOR CANCER BIOMARKERS," is for the development of an automated platform to detect cancer biomarkers. As a Phase I SBIR contract, this award is...